Comparative Pharmacology
Head-to-head clinical analysis: LOESTRIN FE 1 20 versus NYLIA 7 7 7.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LOESTRIN FE 1 20 versus NYLIA 7 7 7.
LOESTRIN FE 1/20 vs NYLIA 7/7/7
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination oral contraceptive consisting of ethinyl estradiol and norethindrone acetate. Inhibits gonadotropin secretion (FSH, LH) via negative feedback on the hypothalamic-pituitary-ovarian axis, suppressing ovulation. Increases cervical mucus viscosity and alters endometrial structure, impeding sperm penetration and implantation.
Combination of ethinyl estradiol and norethindrone; suppresses gonadotropin release, inhibiting ovulation and altering cervical mucus and endometrial lining.
One tablet (norethindrone acetate 1 mg and ethinyl estradiol 20 mcg) orally once daily for 21 consecutive days, followed by one ferrous fumarate tablet (75 mg) orally once daily for 7 days.
One tablet orally once daily, with each tablet containing 0.035 mg ethinyl estradiol and sequentially 0.5 mg, 0.75 mg, 1 mg norgestimate for days 1-7, 8-14, 15-21 respectively, followed by 7 placebo days.
None Documented
None Documented
Norethindrone: 6-9 hours (terminal). Ethinyl estradiol: 13-27 hours (terminal, mean 16 hours). Steady-state reached within 5-7 days.
Terminal elimination half-life is 14 hours (range 10–18 hours). In renal impairment (CrCl <30 mL/min), half-life extends to 30–50 hours, necessitating dose adjustment.
Norethindrone: 50-60% renal (as metabolites), 20-30% fecal. Ethinyl estradiol: 40-50% renal (as glucuronide conjugates), 30-40% fecal (as sulfate conjugates).
Renal (70% as unchanged drug, 10% as active metabolite), fecal (15%), biliary (5%)
Category C
Category C
Combined Oral Contraceptive
Combined Oral Contraceptive